TY - JOUR
T1 - Humanized M195 monoclonal antibody conjugated to recombinant gelonin
T2 - An anti-CD33 immunotoxin with antileukemic activity
AU - Pagliaro, Lance C.
AU - Liu, Baoshun
AU - Munker, Reinhold
AU - Andreeff, Michael
AU - Freireich, Emil J.
AU - Scheinberg, David A.
AU - Rosenblum, Michael G.
PY - 1998/8
Y1 - 1998/8
N2 - The recently characterized immunotoxin HuM195-gelonin consists of a humanized anti-CD33 monoclonal antibody conjugated to the single-chain plant toxin gelonin. Binding of the immunotoxin to hematopoietic cells that express the CD33 differentiation antigen has been demonstrated and results in cytotoxicity due to ribosomal inactivation by gelonin. Blast cells from most patients with acute myelogenous leukemia express CD33, whereas normal stem cells necessary for maintenance of hematopoiesis do not. We asked whether an immunoconjugate using recombinant gelonin rather than plant gelonin is toxic to acute myelogenous leukemia (AML) cell lines and primary AML blasts obtained from patients and exposed to the immunotoxin in vitro. The CD33(pos) cell lines HL60, OCI/AML2, and OCI/AML5 showed decreased proliferation when exposed to immunotoxin for 24-72 h. The CD33(neg) cell line OCI/AML3 was relatively resistant to HuM195, and all cell lines were resistant to equimolar concentrations of unconjugated antibody and gelonin. Primary blast cultures from seven patients with AML had CD33 detectable on 75.7-99.8% of cells by flow cytometry, and all showed dose-dependent decreases in clonogenic cell survival during 24-h incubation with the immunotoxin. Cells selected for low CD33 expression by cell sorting or by prolonged incubation with immunotoxin could reexpress CD33 at baseline levels and remained sensitive to immunotoxin. We conclude that humanized M195 conjugated to recombinant gelonin has antileukemic activity and should be considered for clinical testing in Phase I trials.
AB - The recently characterized immunotoxin HuM195-gelonin consists of a humanized anti-CD33 monoclonal antibody conjugated to the single-chain plant toxin gelonin. Binding of the immunotoxin to hematopoietic cells that express the CD33 differentiation antigen has been demonstrated and results in cytotoxicity due to ribosomal inactivation by gelonin. Blast cells from most patients with acute myelogenous leukemia express CD33, whereas normal stem cells necessary for maintenance of hematopoiesis do not. We asked whether an immunoconjugate using recombinant gelonin rather than plant gelonin is toxic to acute myelogenous leukemia (AML) cell lines and primary AML blasts obtained from patients and exposed to the immunotoxin in vitro. The CD33(pos) cell lines HL60, OCI/AML2, and OCI/AML5 showed decreased proliferation when exposed to immunotoxin for 24-72 h. The CD33(neg) cell line OCI/AML3 was relatively resistant to HuM195, and all cell lines were resistant to equimolar concentrations of unconjugated antibody and gelonin. Primary blast cultures from seven patients with AML had CD33 detectable on 75.7-99.8% of cells by flow cytometry, and all showed dose-dependent decreases in clonogenic cell survival during 24-h incubation with the immunotoxin. Cells selected for low CD33 expression by cell sorting or by prolonged incubation with immunotoxin could reexpress CD33 at baseline levels and remained sensitive to immunotoxin. We conclude that humanized M195 conjugated to recombinant gelonin has antileukemic activity and should be considered for clinical testing in Phase I trials.
UR - http://www.scopus.com/inward/record.url?scp=0031850006&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031850006&partnerID=8YFLogxK
M3 - Article
C2 - 9717827
AN - SCOPUS:0031850006
SN - 1078-0432
VL - 4
SP - 1971
EP - 1976
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 8
ER -